Michael Cruse

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

5

Register now: https://loom.ly/V7hvN_g Join experts from AssistRx and MMIT (Managed Markets Insight & Technology) on Dec. 3 at 1 p.m. ET to discover the strategies life sciences organizations can use to alleviate copay program disruptions in 2025. During the webinar, we’ll detail how the perfect blend of tech and talent can help address recent payer activity, including new payer utilization management strategies and the changing copay accumulator and maximizer landscape. Can’t make it live? Request a recording when you sign up to view on your schedule. #InformedAccess #ImprovedOutcomes

15

See how HCP Message Monitor helped a pharma manufacturer understand message effectiveness and ensure recall in our latest case study. https://ow.ly/UmC750TQitM

7

Integrating real-world datasets with payer policy and restriction data reveals the full scope of the patient journey. https://ow.ly/Atqe50U8hvu In Drug Channels Institute, an HMP Global Company, MMIT’s Kala Bala and Dinesh Kabaleeswaran discuss the evolution of market access and what pharma can accomplish with AI and predictive analytics. #MarketAccess #PharmaInnovation #PredictiveAnalytics #PatientJourney

5

Molecular diagnostic companies with rich patient assay data are in a unique position to leverage this data to address their marketplace challenges. What are the considerations organizations need to consider to create an effective strategy for utilzing their omics real-world data (oRWD)? Read more: https://hubs.ly/Q031NSvc0

2

Payers representing 90% of commercial lives say interchangeability plays a key role in the coverage decision for Humira biosimilars. MMIT’s Catherine Humphries and Julia Scanlan explore adoption and pricing factors in this blog. https://ow.ly/8nMY50QeUNY #HumiraBiosimilars #Pharma #Pharmaceuticals

7

Integrating real-world datasets with payer policy and restriction data reveals the full scope of the patient journey. https://ow.ly/IRgL50U8huJ In Drug Channels Institute, an HMP Global Company, MMIT’s Kala Bala and Dinesh Kabaleeswaran discuss the evolution of market access and what pharma can accomplish with AI and predictive analytics. #MarketAccess #PharmaInnovation #PredictiveAnalytics #PatientJourney

7

New Blog Post Alert! Our latest blog highlights how Prescient supported a mid-size, oncology-focused pharmaceutical company in transforming its evidence-generation capabilities. This post showcases how proactive, strategic planning can enable impactful evidence generation that drives real-world success. Read more: https://bit.ly/3YY7Tef #Biopharma #EvidenceGeneration #OrganizationalTransformation #Oncology

19

Patient Blood Management #pbm is leading a global revolution in anemia care, uniting a diverse network of organizations, medical centers, and advocates. As the premier strategy for addressing iron deficiency, PBM has become essential in the fight against anemia. The challenge is demonstrating a collective commitment to this cause. Success in this battle relies not on individual voices but on presenting a unified front. Just as wars are won by clearly recognized and united armies, not by isolated teams, success depends on showing that everyone involved is fighting the same war. To this end, the #Anemia Emblem is introduced—a symbol of the shared mission and a clear sign of unity in this effort. This emblem represents true global innovation and growth, serving as a powerful, global identifier that showcases to patients, healthcare providers, and the public the unified dedication to managing anemia through PBM. Each time the Anemia Emblem is seen, it reinforces the joint effort and underscores the importance of PBM in improving anemia care worldwide. Just as the NO BLOOD emblem has long symbolized patients' preferences, the Anemia Emblem will become a recognized mark of collective commitment to battling anemia. By uniting under this emblem, the resolve is strengthened, demonstrating that together, a significant difference is being made. Time is not on our side in this battle. The sooner the recognition, the sooner the momentum will occur in saving the lives of others and managing the use of patients' blood.

3

We recently discussed the impact of the Inflation Reduction Act (IRA) on drug development, featuring views from biotech and patient advocacy. Read the summary and key takeaways: https://buff.ly/3ZH88L5 On-Demand webinar available: https://buff.ly/3ZEbD4N #IRA #DrugDevelopment #Pharma #RareDisease #Biotech #BioPharma #StrategyConsulting #HealthcareStrategy #PatientAdvocacy

11

4 Comments

📹 In part 2 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions highlights how #artificialintelligence can help industry keep pace with the increasing complexity of data.

17

1 Comment

Integrating real-world datasets with payer policy and restriction data reveals the full scope of the patient journey. https://ow.ly/5bsI50U8hxh In Drug Channels Institute, an HMP Global Company, MMIT’s Kala Bala and Dinesh Kabaleeswaran discuss the evolution of market access and what pharma can accomplish with AI and predictive analytics. #MarketAccess #PharmaInnovation #PredictiveAnalytics #PatientJourney

6

Biomedtracker and Evaluate Ltd Pharma are available via Snowflake. Access real-time tracking and analysis of the drug development pipeline and navigate the complex commercial, clinical, and regulatory landscape with precision: https://ow.ly/NcZ250ThuSQ.

7

See how HCP Message Monitor helped a pharma manufacturer understand message effectiveness and ensure recall in our latest case study. https://ow.ly/JySl50TQiuB

8

See how HCP Message Monitor helped a pharma manufacturer understand message effectiveness and ensure recall in our latest case study. https://ow.ly/y9Ra50TQirS

6

📣 OneOncology's Oncology Quality Hub has been approved by CMS as both a Qualified Clinical Data Registry (QCDR) and a Qualified Registry (QR). 🔍 This designation reflects OneOncology’s ability to meet rigorous federal standards for collecting and submitting clinical data on behalf of healthcare providers as part of CMS’s Quality Payment Program (QPP). ⛏️ As a CMS-approved QCDR and QR, OneOncology can now collect clinical data from a variety of sources and report MIPS measures for partner clinicians and practices regardless of their EMR provider, streamlining quality reporting and driving improved performance. 🩺 As a QCDR, OneOncology is now also authorized to develop new quality measures that CMS can recognize and incorporate into the MIPS program. ⬇️ Check out the news release. https://lnkd.in/ewZEn28n

77

3 Comments

Pharma companies can help patients access biomarker testing by providing resources on patient identification, available vendors, proof of eligibility, and ordering instructions. MMIT and The Dedham Group share tips for oncology manufacturers in Drug Channels: https://ow.ly/G3IV50RFHhz. #Pharma #PharmaManufacturers #MarketAccess #Oncology

7

The frequency of payer/pharma meetings has increased, but the duration has decreased in the past year. https://ow.ly/wqe150SmI7p MMIT's Jonathan Cecire and Norstella's Dinesh Kannan Kabaleeswaran look at what the latest trends tell us about how pharma companies can advocate for better formulary positioning for their products. #PharmaCompanies #PharmaInsights #Formularies

8

Clinical trial data management is a challenge for many research organizations, leading to data quality issues and backlogs, among other issues. Omega Healthcare CurateIQ offers data management solutions for data curation and analytics to improve cancer care. Download our white paper to learn more: https://buff.ly/4cB55qI #RealWorldEvidenceData #ClinicalTrialDataManagement #CancerRegistry #OncologyDataSpecialists #RWD #RWE

35